virus asymptomatically infects more than 95% of healthy adults worldwide. However, EBV is also an oncogenic herpesvirus associated with various neoplastic diseases, such as lymphoproliferative diseases in immunocompromised patients, various lymphomas and epithelial cancers.
invariably associated with an immunosuppressed state caused by chronic malaria infection. 11 Thus, endemic Burkitt lymphomas are most likely caused by environmental factors.
Nasopharyngeal carcinoma is an EBV-associated epithelial carcinoma, and is common in South China and Southeast Asia ( Figure 1 ). 12 More than 97% of NPC are EBV-positive, 13 and the tight link between NPC and EBV is observed worldwide. 3 Several predisposing factors have been postulated, including host immune-related genes such as human leukocyte antigens, 14 and environmental factors such as dietary habits (i.e. eating salted fish). 15 In addition, genetic and epigenetic aberrations of host cells drive NPC development and progression. 16 On the other hand, it has long been known that distinct EBV strains are predominant in areas with a high incidence of NPC. 17 This suggests that EBV strain variation contributes to the endemic nature of NPC.
Another EBV-associated disease with a distinct geographic distribution pattern is EBV-associated T/NK lymphoma. Although T/NK lymphoma is a rare disease, it occurs with relatively high frequency in East Asia including Japan and Korea, 18, 19 where the incidence of NPC is relatively low. Thus, NPC endemic areas do not coincide with areas of relatively high incidence of T/NK lymphomas, although it is possible that they substantially overlap.
The reason why EBV is associated with different malignancies in different areas within Asian countries is not clear. One possible explanation is differences in host genetic backgrounds; however, another explanation is differences in EBV strains that colonize different areas in Asia.
Another malignancy causally associated with EBV infection is
EBVaGC. 20 EBVaGC account for approximately 9% of all gastric cancers, 13 and show no biased geographic distribution. The EBV infection causes CpG island methylation of host chromosomes and EBV genome DNA methylation as well. 21 Chromosomal CpG methylation may trigger epithelial carcinogenesis through silencing of tumor suppressor genes. 21, 22 There is a possibility that EBVaGC are caused by oncogenic variants of EBV, which are functionally distinct from those derived from lymphoid cells.
| EBV G ENOME S TRUC TURE AND S EQUEN CING

| EBV genome
Epstein-Barr virus has a linear dsDNA genome of approximately 175 kb (Figure 2 ), which is circularized in latently infected cells. The prototypical strain B95-8 was the first complete EBV genome sequenced using a conventional strategy (i.e. subcloning followed by Sanger sequencing) (GenBank accession no. X01555.2). 23 Subsequently, the sequence of a putative "wild-type" EBV strain was artificially created by repairing the 12-kb defect of the B95-8 strain ( Figure 2 ) 24 with the corresponding sequence of the Raji strain EBV 25 (EBV-wt, 26 GenBank accession no. NC_007605.1). The EBV genome encodes more than 80 ORF, several non-coding RNA (EBER1 and EBER2), 1 and 44 mature miRNA. 27 Viral genes that are specifically expressed in latently infected cells are called "EBV latent genes". 28 Among latent gene products, four EBNA (EBNA1, EBNA2, EBNA3A and EBNA3C) and LMP1 are essential for B-cell transformation. 1 Viral genes that are specifically expressed during the productive replication cycle are called "EBV lytic genes" (Figure 2 ). Lytic genes encode viral transcription factors (e.g. BZLF1), a viral DNA polymerase (BALF5) and associated factors, and viral glycoproteins (e.g. gp350/220 and gp110) and structural proteins (capsid and tegument proteins) ( Figure 2 ).
The EBV genome has various repetitive sequences scattered throughout the viral genome, such as within the coding regions of viral latent proteins or near the viral replication origins ( Figure 2 
EBNA3A,3B,3C F I G U R E 3 Experimental strategies to sequence whole Epstein-Barr virus (EBV) genomes. (Left) For the hybrid capturemediated sequencing, the prepared DNA, consisting of host cell DNA (black) and viral DNA (red), were fragmented and hybridized with biotin (green)-labeled RNA probes spanning the EBV genome. Captured EBV DNA were then subjected to deep sequencing using a short-read sequencer. (Right) For EBV-bacterial artificial chromosome (BAC) cloning, a linear targeting vector was transfected into EBV latently infected cells to obtain homologous recombinants. Alternatively, a circular donor plasmid and a CRISPR/ Cas9 plasmid were co-transfected into the cells to increase the homologous recombination efficiency. was developed. The method was applied to readily determine eight EBV strains derived from NPC biopsy specimens. 30 The same experimental strategy was used by the group of Farrell and colleagues to sequence 71 EBV strains derived from various areas of the world. 36 The sequenced materials include various EBV disease-derived cell lines, spontaneously arising LCL, NPC tumor and biopsy samples, and saliva.
Many of the Asian strains in the dataset were from Southern China, an NPC endemic area, and a few were from Japan and South Korea. This analysis clearly separated Asian EBV strains from those derived from the rest of the world.
The number of available EBV sequences is increasing exponentially (Figure 4) , and approximately 200 EBV genomes have been sequenced by the group of Farrell and colleagues. 36, 37 Eighteen additional EBV strains derived from NPC biopsy specimens 38 and nine EBV strains derived from biopsy specimens of Chinese EBVaGC patients 39 were sequenced by other groups.
One drawback of the hybrid capture approach is that repetitive sequences ( Figure 2 ) cannot be determined because the method uses short-read sequencers. 36 Most of the repetitive regions therefore remain to be sequenced. Another drawback is that sequence assembly becomes difficult when multiple EBV strains are present in the material, which is often the case in the saliva of healthy individuals 40, 41 and that of infectious mononucleosis patients. 42 
| Cloning of the EBV genome and sequencing
To circumvent the problems associated with the hybrid capture method, the DNA of each EBV genome can be cloned prior to sequencing. Cloning of EBV genomes can be achieved by inserting a BAC vector sequence into EBV episomes in EBV latently infected cells through homologous recombination (Figure 3 ). The experimental strategy was pioneered by the group of Hammerschmidt and colleagues 43 using the prototype B95-8 strain as the starting material, followed by BAC cloning of the Japanese Burkitt lymphoma-derived Akata strain by our group. 44 The experimental strategy was recently applied to the Chinese NPC-derived EBV M81 strain, 45 which had not been sequenced previously. The obtained M81 EBV-BAC was sequenced using a short-read sequencer and Sanger sequencingmediated gap filling. Phylogenetic analysis indicated that M81 is closely related to other NPC strains (GD2 and HKNPC1), whereas it is distant from other strains (B95-8 and Mutu). 45 We recently improved the EBV-BAC cloning efficiency using CRISPR/Cas9-mediated genome editing technology to introduce a single cut at the transgene insertion site and stimulate homologous recombination (Figure 3) . 46 Year strategy into a high-throughput method is difficult. However, one advantage of EBV-BAC cloning is that it can be used to clone multiple strains that coexist in a single specimen. In addition, purified EBV-BAC clone DNA can be used to reconstitute infectious viruses and examine their phenotypes (Figure 3 , see below).
| EBV G ENOME HE TEROG ENEIT Y
| Overview of viral genome heterogeneity
A methodology formerly used to detect EBV strain variation is detection of restriction fragment length polymorphisms by means of Southern blot. 17, 40 Sanger sequencing of specific viral genes (e.g.
LMP1, EBNA1, BZLF1)
was later used to detect sequence diversity.
Genome-wide analysis is becoming possible based on the results of high-throughput sequencing. Although relatively little attention has been paid to the heterogeneity of viral lytic genes, it is becoming clear that they play significant roles in EBV-mediated tumorigenesis.
Relatively large deletions within the EBV genome have also been detected in B95-8 strain 24 and in several Burkitt lymphoma-derived strains. 50 In the following sections, we summarize recent findings of viral genome heterogeneity related to cancer.
| Viral latent gene heterogeneity and deletions in cancer
The essential roles of viral latent proteins in EBV-mediated transformation have prompted an extensive analysis of latent gene heterogeneity, especially that of LMP1. [5] [6] [7] [8] [9] LMP1 genes are classified into six patterns, namely China 1, China 2, Alaskan, Mediterranean, NC (North Carolina) and B95-8. 51 The functional differences between the LMP1 of epithelial cancer-derived EBV (CAO-LMP1, belonging to China 1 type) and lymphoid-derived EBV (B95-8 type) are well-characterized. 52 NPCderived CAO-LMP1 is less cytostatic than B95-8 LMP1 ( Figure 5 ). 53 Such functional difference is attributed to amino acid differences in the transmembrane domain of LMP1, and is not related to the 30-bp deletion in the carboxy-terminal cytoplasmic domain. 53 Functional differences in LMP1 most likely contribute to differences in viral phenotypes, although this remains to be experimentally verified.
It was previously demonstrated that EBNA3B acts as a tumor suppressor ( Figure 5 ). 54 Recombinant EBV lacking the EBNA3B gene shows higher B-cell-transforming ability than the wild type, and EBV-transformed B cells lacking the EBNA3B gene expand more rapidly in mice than those having the EBNA3B gene. EBNA3B mutations were detected in various EBV-positive human lymphoma samples, 54 suggesting that EBV strains with EBNA3B gene mutations are selected in these tumors.
Deletion of the EBNA2 gene is commonly found in Burkitt lymphoma-derived cell lines, such as P3HR-1 and Daudi ( Figure 5 ). 50 The EBV genome lacking the EBNA2 gene shows a specific latent gene expression pattern 55 characterized by the expression of BHRF1
(a viral counterpart of cellular blc-2), which confers anti-apoptotic activity to Burkitt lymphoma cells ( Figure 5 ). This suggests that the EBV genome with deletion of the EBNA2 gene is selected to confer growth advantages during Burkitt lymphomagenesis.
Another well-characterized EBV alteration is the region deleted in the B95-8 strain ( Figure 5 ). The B95-8 deletion removes most of the BART miRNA sequences and one lytic origin of replication 
| Viral lytic gene heterogeneity in cancer
Research interest has focused on a viral BZLF1 gene, a master regulator of viral lytic replication. 1 BZLF1 is highly polymorphic both for its coding sequence and promoter region. 7, 60 When the NPC-derived M81 strain was reconstituted and used to immortalize B lymphocytes, M81 EBV spontaneously replicated at unusually high levels in established LCL. 45 This is consistent with the observation that NPC patients have unusually high antibody titers against EBV lytic proteins. 2 The propensity to enter lytic infection is believed to enhance the malignant potential in animal models of lymphomagenesis. 61 A recent study further demonstrated that sequence variation of the BZLF1 promoter region of M81 EBV contributes to the property to enter the lytic cycle. 60 The M81 virus and other epithelial cancer-derived EBV strains show high propensities to infect epithelial cells. 45, 62 Epitheliotropism is apparently advantageous for the virus to increase the chance to infect the nasopharyngeal epithelium. The viral gB protein (gp110) of the M81 strain is at least partly responsible for the enhanced tropism toward epithelial cells ( Figure 5 ). 
| Other heterogeneities possibly affecting carcinogenesis
Subtle variations of repetitive sequences, such as those of FR 63 and IR1, 64 can significantly affect viral phenotypes. The IR1 heterogeneity generates a modestly defective EBNA-LP and has a detrimental impact on B-cell transforming ability ( Figure 5 ). 64 Sequence variations of EBV genes also result in amino acid epitope exchanges, which should have a significant impact on EBVspecific T-cell immunity. 65 EBV latency-associated gene products, especially EBNA3, are targets of immune recognition during persistent infection. A higher frequency of SNP and a higher ratio of nonsynonymous amino acid changes in latency-associated genes suggest that these genes are evolving under positive selection to escape host immunity ( Figure 5 ). 36 Sequence polymorphisms of LMP2A, an EBVencoded B-cell receptor mimic, have been detected in clinical isolates from various diseases, but their pathogenetic roles remain unclear. 
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